Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort

Table 1 Characteristics of inflammatory bowel disease patients and incident venous thromboembolism in the UK Biobank

	Subjects, n (%)	Age dx, median (IQR), yr	Incident VTE, n (%)
IBD, all	8465 (1.68)	50.08 (35.24-61.76)	398 (4.7)
Crohn's disease	2267 (0.45)	49.68 (32.48-62.37)	101 (4.46)
Ulcerative colitis	5233 (1.05)	51.38 (36.87-62.50)	235 (4.49)
Indeterminate colitis	965 (0.19)	44.26 (31.56-54.92)	62 (6.42)

IBD: Inflammatory bowel disease; VTE: Venous thromboembolism.

Table 2 Association of venous thromboembolism risk with F5/F2 mutations and polygenic score in the UK Biobank

	IBD patients, n (%)	Incident VTE, n (%)	HR (95%CI)1	P value
FVL/F2 carrier status
Non-carriers	7701/8210 (93.8)	332/7701 (4.31)	Ref.
FVL carriers	351/8210 (4.28)	37/351 (10.54)	2.27 (1.61-3.21)	2.84E-06
F2 carriers	163/8210 (1.99)	10/163 (6.13)	1.29 (0.69-2.43)	0.43
Any FVL/F2 carriers	509/8210 (6.2)	46/509 (9.04)	1.94 (1.42-2.65)	3.27E-05
PGSnon-F5/F2 decile
Bottom	821/8210 (10)	13/821 (1.58)	0.36 (0.21-0.63)	3.12E-04
Intermediate	6568/8210 (80)	295/6568 (4.49)	Ref.
Top	821/8210 (10)	70/821 (8.53)	1.98 (1.52-2.57)	3.26E-07

¹HR adjusted for gender, body mass index, and genetic background. The time in survival analysis was from inflammatory bowel disease to event.

IBD: Inflammatory bowel disease; VTE: Venous thromboembolism; 95%CI: 95% confidence interval; HR: Hazard ratio.

Table 3 Discriminative performance of venous thromboembolism by inherited risk factors

	AUC (95%CI)1
F5/F2 mutations	0.64 (0.61-0.67)
PGSnon-F5/F2	0.68 (0.65-0.71)
F5/F2 mutations + PGSnon-F5/F2	0.69 (0.66-0.71)
PGS	0.69 (0.67-0.72)

¹Model also included age, gender, body mass index and genetic background.

AUC: Area under the receiver operating characteristic curve; PGS: Polygenic score; 95%CI: 95% confidence interval.